Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia.

Slides:



Advertisements
Similar presentations
CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,
Advertisements

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia by Nathalie Dhédin, Anne Huynh, Sébastien.
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with.
Maury S et al. Proc ASH 2015;Abstract 1.
Secondary or Concomitant Neoplasms among Adults Diagnosed with Acute Lymphoblastic Leukemia (ALL) and Treated According to the LALA-87 and LALA-94 Trials.
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.
A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose.
TCR-MHC-peptide(s): in vivo veritas
Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology.
Finding a diamond in the (mouse is) rough
Next-generation leukemia immunotherapy
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.
Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,
Gupta V, Tallman MS, Weisdorf DJ
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group by.
Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.
Tax fingerprint in adult T-cell leukemia
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group.
NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on.
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia by Yves Chalandon, Xavier.
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid.
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
Acute promyelocytic leukemia, microgranular variant
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first.
Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute.
Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric.
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
by J. Rodriguez, M. A. Rodriguez, L. Fayad, P. McLaughlin, F. Swan, A
Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.
Granulocyte Colony-Stimulating Factor as an Adjunct to Induction Chemotherapy for Adult Acute Lymphoblastic Leukemia — A Randomized Phase-III Study by.
Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.
Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J
by John Anastasi, Rizwan Moinuddin, and Christopher Daugherty
Jacob M. Rowe  Biology of Blood and Marrow Transplantation 
Immunotherapy for acute lymphoblastic leukemia: from famine to feast
Blinatumomab Versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.
by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF ) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic.
Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.
Bigger, Stronger, Faster: Chimeric Antigen Receptor T Cells Are Olympic Killers by Paul J Neeson, Alexander James Davenport, Joseph A Trapani, Michael.
Outcome of treatment in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial.
A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia by Nicola Gökbuget, Hervé Dombret, Massimiliano.
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG.
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.
Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed.
Cold agglutinin disease
Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor.
Presentation transcript:

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)‏ by Max S Topp, Zachary Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, Andre C. Schuh, Janet Franklin, Kun Nie, and Ze Cong Blood Volume 128(22):222-222 December 2, 2016 ©2016 by American Society of Hematology

Max S Topp et al. Blood 2016;128:222 ©2016 by American Society of Hematology

Max S Topp et al. Blood 2016;128:222 ©2016 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.